Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
Michael Ahlijanian, PhD is a drug discovery professional and talented leader with more than 25 years in the pharma/biotech industry. His expertise is in Neuroscience. Dr. Ahlijanian has had success in preclinical candidate delivery and translating preclinical data sets to the clinic, as well as developing therapeutics and translational data sets for Duchenne’s muscular dystrophy.
Former VP of Research, EnVivo Pharmaceuticals
Former Director of Neuroscience and Genetically Defined Diseases Biology and Head, Clinical Biomarkers GDD, Bristol Myers Squibb
Former Executive Director of CNS Discovery, Pfizer